Arcus Biosciences (RCUS) Income from Continuing Operations (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly Income from Continuing Operations came in at 128000000.0 in Q1 2026, down 14.29% year-on-year from 149333333.33 in Q1 2025, and down 20.75% quarter-over-quarter from 106000000.0 in Q4 2025.
Arcus Biosciences (RCUS) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Arcus Biosciences' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 128000000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 14.29% year-over-year to 128000000.0 in Q1 2026; TTM through Mar 2026 was 369000000.0, a 5.63% increase from a year earlier, with the FY2025 full-year figure at 353000000.0, down 24.73% from the prior year.
- Income from Continuing Operations declined to 128000000.0 in Q1 2026 per RCUS's latest filing, from 106000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4000000.0 in Q1 2024 and bottomed at 135000000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 80500000.0 (2023), against an average of 83625000.0.
- Across the five-year window, Income from Continuing Operations soared 95.0% in 2024 and sank 2700.0% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 67000000.0 in 2022, then declined by 20.9% to 81000000.0 in 2023, then slipped by 16.05% to 94000000.0 in 2024, then declined by 12.77% to 106000000.0 in 2025, then dropped by 20.75% to 128000000.0 in 2026.
- Per Business Quant, the three latest RCUS Income from Continuing Operations figures stand at 128000000.0 (Q1 2026), 106000000.0 (Q4 2025), and 135000000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Arcus Biosciences | 3.57 Bn | 2.75 Bn | - | -128.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -106.00 Mn |
| Sep 30, 2025 | -135.00 Mn |
| Mar 31, 2025 | -112.00 Mn |
| Dec 31, 2024 | -94.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | -4.00 Mn |
| Dec 31, 2023 | -81.00 Mn |
| Sep 30, 2023 | -71.00 Mn |
| Jun 30, 2023 | -75.00 Mn |
| Mar 31, 2023 | -80.00 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -67.00 Mn |
| Mar 31, 2022 | -68.00 Mn |
| Dec 31, 2021 | 279.54 Mn |
| Sep 30, 2021 | -77.98 Mn |
| Jun 30, 2021 | -75.97 Mn |
| Mar 31, 2021 | -72.59 Mn |